Income StatementBalance SheetCash FlowSegments
Pfizer logo

Pfizer Business Segments

Business, geographic, and product segment breakdowns

Pfizer generates $63.3B in annual revenue across 1 key segments: Business Segments ($14.2B). Based on the Q1 2026 filing.

Business Segments (TTM)$14.2B
Latest FilingQ1 2026
Report Date2026-05-05
Market Cap$147.62B
P/E Ratio12.19
ROE13.42%

Products & Services

Revenues:

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Eliquis$1.8B$1.9B$2.0B$2.0B$2.0B$2.2B
Prevnar Family$1.6B$1.7B$1.4B$1.7B$1.7B$1.7B
Vyndaqel family$1.5B$1.5B$1.6B$1.6B$1.7B$1.6B
Ibrance$1.1B$977.0M$1.0B$1.1B$1.0B$1.0B
All Other Hospital and Biosimilars—$901.0M———$953.0M
All other Primary Care$787.0M$609.0M$736.0M$721.0M$789.0M$654.0M
Padcev$444.0M$426.0M$542.0M$464.0M$508.0M$591.0M
All other Specialty Care$344.0M$486.0M$390.0M$407.0M$476.0M$579.0M
Xtandi$565.0M$458.0M$566.0M$578.0M$592.0M$444.0M
Oncology Biosimilars$209.0M$264.0M$353.0M$315.0M$369.0M$409.0M
All other Oncology$285.0M$377.0M$380.0M$272.0M$303.0M$376.0M
Nurtec ODT/Vydura$393.0M$248.0M$359.0M$412.0M$405.0M$353.0M
Lorbrena$193.0M$222.0M$251.0M$268.0M$282.0M$305.0M
Pfizer CentreOne$326.0M$273.0M$328.0M$344.0M$409.0M$289.0M
Comirnaty$3.4B$565.0M$381.0M$1.2B$2.3B$232.0M
Inlyta$242.0M$219.0M$243.0M$226.0M$235.0M$214.0M
Sulperazon (Outside the U.S. and Canada)$169.0M$164.0M$166.0M$154.0M$169.0M$199.0M
Adcetris$285.0M$218.0M$255.0M$215.0M$220.0M$190.0M
Paxlovid—$491.0M$427.0M$1.2B—$186.0M
Inflectra—$153.0M$139.0M$173.0M—$182.0M
Abrysvo$198.0M$131.0M$143.0M$279.0M$480.0M$180.0M
Xeljanz$350.0M$128.0M$322.0M$313.0M$324.0M$180.0M
Braftovi/Mektovi$170.0M$136.0M$182.0M$202.0M$197.0M$174.0M
Zavicefta (Outside the U.S. and Canada)$159.0M$135.0M$163.0M$158.0M$181.0M$150.0M
Enbrel (Outside the U.S. and Canada)$183.0M$140.0M$154.0M$154.0M$179.0M$138.0M
Bosulif$171.0M$151.0M$149.0M$150.0M$161.0M$129.0M
Octagam$109.0M$88.0M$97.0M$113.0M$120.0M$122.0M
Tukysa$129.0M$102.0M$132.0M$110.0M$119.0M$122.0M
Zithromax$123.0M$158.0M$56.0M$73.0M$113.0M$112.0M
Orgovyx$65.0M$76.0M$97.0M$112.0M$136.0M$109.0M
Genotropin$112.0M$95.0M$106.0M$128.0M$117.0M$93.0M
FSME-IMMUN/TicoVac$34.0M$63.0M$109.0M$100.0M$47.0M$81.0M
Elrexfio$57.0M$60.0M$85.0M$85.0M$74.0M$80.0M
Cibinqo$63.0M$58.0M$69.0M$79.0M$78.0M$76.0M
Talzenna$26.0M$40.0M$46.0M$47.0M$49.0M$50.0M
Tivdak$37.0M$33.0M$46.0M$37.0M$32.0M$33.0M

Remaining performance obligation

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Comirnaty$4.0B$3.0B$4.0B$3.0B$2.1B$2.1B

Intangible asset impairments

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Tukysa$400.0M$205.0M$205.0M$205.0M$205.0M—

Total revenues

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Excluding Comirnaty and Paxlovid$12.8B$13.6B$13.6B$13.6B$13.6B—

Finite-lived intangible assets period increase (decrease)

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Padcev—$150.0M$150.0M$150.0M$150.0M—

Indefinite-lived intangible assets, period increase (decrease)

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Tukysa—————-$580.0M
Padcev—-$150.0M-$150.0M-$150.0M-$150.0M—

Contract with Customer, Liability, Current

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Paxlovid and Comirnaty$1.4B$932.0M$1.0B$790.0M$689.0M$646.0M

Deferred revenue recognized

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Paxlovid and Comirnaty$600.0M$335.0M$45.0M$96.0M$295.0M$58.0M

Deferred revenues

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Paxlovid and Comirnaty$2.2B$1.9B$1.9B$1.8B$1.5B$1.5B

Deferred revenues, noncurrent

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Paxlovid and Comirnaty$785.0M$977.0M$906.0M$1.0B$826.0M$816.0M

Revenue

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Royalty$431.0M$308.0M$426.0M$436.0M$480.0M$396.0M

Concentration risk, amount

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Top Eleven Products$250.0M$250.0M$250.0M$250.0M$250.0M—

Concentration risk, percentage

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Top Twelve Products—16.3%16.3%16.3%16.3%—

Alliance revenues

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Total Alliance revenues$2.2B$2.1B$2.3B$2.3B$2.6B$2.3B

Finite-lived intangible assets, period increase

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Tukysa—————$580.0M

Geographic

Property, plant and equipment, net

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Developed Markets$7.2B———$8.2B—
Emerging Markets$1.5B———$1.5B—
U.S.$9.7B———$9.7B—

Revenues:

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
U.S.$9.2B$8.4B$8.9B$10.7B$9.1B$8.7B
International Developed Markets$6.3B$3.2B$3.4B$3.7B$5.9B$3.4B
International Emerging Markets$2.3B$2.2B$2.4B$2.3B$2.5B$2.3B

Number of countries with revenue exceeding $500 million

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Outside United States1100.0%———1200.0%—

Business Segments

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Revenues:$17.4B$13.4B$14.3B$16.3B$17.1B$14.2B
Income from continuing operations before provision/(benefit) for taxes on income$6.3B$7.1B$6.9B$8.5B$6.9B$6.8B
Expected restructuring cost$2.2B$2.4B$3.7B$3.7B$3.7B$3.7B
Restructuring cost incurred to date$2.1B$2.7B$2.7B$2.9B$3.2B$3.3B
Cost of Sales$5.3B$2.3B$3.1B$3.5B$4.6B$3.0B
Research and development expenses$2.7B$1.9B$2.1B$2.2B$2.9B$2.1B
Selling, informational and administrative expenses$3.1B$2.2B$2.3B$2.2B$2.9B$2.1B
D&A$342.0M$331.0M$339.0M$358.0M$350.0M$348.0M
Acquired in-process research and development expenses$88.0M$9.0M$2.0M$40.0M$62.0M$137.0M
Other Nonoperating Income (Expense)$51.0M$78.0M$115.0M$120.0M$268.0M$116.0M
Investment Income, Dividend$89.0M$39.0M$73.0M$72.0M$81.0M$82.0M
Provision$500.0M$617.0M-$408.0M$240.0M$2.2B$47.0M